We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Glyn Edwards MBE Joins OxSonics’ Board as Non-Executive Director
News

Glyn Edwards MBE Joins OxSonics’ Board as Non-Executive Director

Glyn Edwards MBE Joins OxSonics’ Board as Non-Executive Director
News

Glyn Edwards MBE Joins OxSonics’ Board as Non-Executive Director

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Glyn Edwards MBE Joins OxSonics’ Board as Non-Executive Director"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

OxSonics Limited, a world leader in the development of ultrasound-based drug delivery systems for the treatment of cancer patients, announced that Glyn Edwards is to join the board as Non-Executive Director.

Glyn Edwards has held the position of CEO of Summit plc since April 2012 where he has restructured the business, taken the company through a NASDAQ listing and focused on its infectious and rare disease clinical development programs. Prior to joining Summit, Mr Edwards served as interim CEO of the BioIndustry Association (BIA), a UK trade organisation, from November 2011 to June 2012, and as CEO at Antisoma plc, a biotechnology company specialising in the development of novel drugs for the treatment of cancer, from 1998 to 2011. Mr Edwards received a BSc in Biochemistry from Bristol University and a MSc in Economics from the London Business School. Mr Edwards was awarded an MBE for his services to the biotechnology industry in 2006.

Dr. Colin Story, Chief Executive Officer commented: “Glyn Edwards brings over four decades of transactional and leadership expertise not just in oncology but also in a range of other therapeutic areas. Glyn is also exceptionally well networked in the industry. I’m very pleased to welcome Glyn to the board at this very exciting time in the company’s history – as we are poised to translate OxSonics drug delivery platform, SonoTran, into clinical use.”

Glyn Edwards commented: “I’m excited to be joining OxSonics at this important point in its development. The company is soon to demonstrate the huge value of the technology and I’m really looking forward to helping OxSonics realise its full potential.”

Advertisement